ClinicalTrials.gg
RecruitingNCT07027514Updated Sep 2, 2026

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

A Phase 1 interventional study of tolododekin alfa and Cetrelimab in Non Small Cell Lung Cancer, sponsored by Ankyra Therapeutics, Inc. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Ankyra Therapeutics, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
1,414th of 2,995
60 · median 56
Started
2025
with 148 others
Phase 1
927 of 3,368
134 open now
Primary completion
2027-06
later than 400 of 892 live
Registered
3,186th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,414th largest by planned enrollment of the 2,995 interventional ones that give a count, is one of 149 that started in 2025, is one of 927 in phase 1, reaches primary completion later than 400 of the 892 other live ones, and was the 3,186th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have confirmed locally advanced or NSCLC
  2. Thyroid-stimulating hormone (TSH) within normal limits
  3. Have per version 1.1 (RECIST v1.1)
  4. performance status (ECOG PS) 0 to 1
  5. Have a > 12 weeks
  6. Have baseline (ECG) without evidence of acute ischemia or prolonged
  7. Heterosexually active women of (WOCBP) must agree to use highly effective methods of
  8. Male participants who are not sterile must commit to the use of a reliable method of birth control or abstinence
  9. (HIV)-infected participants must be on anti-retroviral therapy (ART) and have well-controlled HIV infection/disease
  10. Resolution of all prior anticancer therapy toxicities prior to C1D1.
  11. Willingness to provide fresh tumor specimens
  12. Capable of understanding and complying with protocol requirements
  13. Provides written for the study

Exclusion criteria

Exclusion Criteria:

  1. Cohort A only: Participants with toxic effects to manage adverse events from previous treatment with immunotherapy
  2. Cohort B only: Prior therapy with an .
  3. Have known EGFR or ALK mutations
  4. Have had prior treatment with recombinant interleukin-12 (IL-12)
  5. Have received short-term systemic therapy with agents prior to C1D1
  6. Have active disease or medical conditions requiring chronic or other immunosuppressive therapy prior to C1D1
  7. Have received prior to C1D1
  8. Have primary or acquired immunodeficient states
  9. Female participant who is pregnant or breastfeeding
  10. Have a history of allogeneic tissue/solid organ transplant
  11. Has active virus (HBV) or virus (HCV).
  12. -infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease
  13. Have known active central nervous system
  14. Have congestive heart failure, active coronary artery disease, unevaluated new onset angina, unstable angina, or cardiac arrhythmias.
  15. Have uncontrolled bleeding disorders prior to C1D1
  16. Participants on coumadin (warfarin), due to potential for increased bleeding risk associated with surgery
  17. History of noninfectious pneumonitis
  18. Cohort A only: History of allergy to protein-based therapies, history of any significant drug allergy, or known allergies, , or intolerance to cetrelimab OR Cohort B only: Hypersensitivity to any component of the anti-PD-1/PD-L1 antibody selected as standard of care
  19. Have other systemic conditions or organ abnormalities that may interfere with the conduct of the study
  20. Have any acute or chronic psychiatric problems or substance abuse disorder that make the participant unsuitable for participation
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cohort A

    Participants will receive up to 8 cycles of tolododekin alfa in combination with cetrelimab given for up to 1 year

    Drug: tolododekin alfa · Drug: Cetrelimab

  • Experimental
    Cohort B

    Participants will receive up to 8 cycles of tolododekin alfa in combination with the Investigator's choice of a Food and Drug Administration (FDA)-approved anti-PD-1/PD-L1 antibody given according to the FDA-approved label

    Drug: tolododekin alfa

Interventions

  • Participants will receive tolododekin alfa as an intratumoral injection every 3 weeks (Q3W).

  • Participants will receive cetrelimab Q3W.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

    Percentage of participants with complete response (CR) or partial response (PR) among all response evaluable participants

    Time frame: 6 months

Secondary outcomes

  1. Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Number of participants with adverse events (TEAEs, SAEs)

    Time frame: 6 months

  2. Duration of Response (DoR)

    Time from first CR/PR to the date of progressive disease (PD) or death.

    Time frame: 6 months

  3. Disease Control Rate (DCR)

    The percentage of participants with stable disease, complete response or partial response among all response evaluable participants

    Time frame: 6 months

  4. Progression Free Survival (PFS)

    The duration from the first dose of tolododekin alfa until PD/death

    Time frame: 6 months

  5. Overall Survival (OS)

    The length of time participants remain alive starting from the first dose of tolododekin alfa

    Time frame: 6 months

  6. Lesion-level response in injected and noninjected lesions

    Measure response in injected and noninjected lesions

    Time frame: 6 months

  7. Measure of area under the plasma concentration-time curve (AUC) of tolododekin alfa

    Characterize pharmacokinetic (PK) parameter AUC after IT injection of tolododekin alfa

    Time frame: 6 months

  8. Measure of maximum plasma concentration (Cmax) of tolododekin alfa

    Characterize pharmacokinetic (PK) parameter Cmax after IT injection of tolododekin alfa

    Time frame: 6 months

  9. Measure of time to maximum concentration (Tmax) of tolododekin alfa

    Characterize pharmacokinetic (PK) parameter Tmax after IT injection of tolododekin alfa

    Time frame: 6 months

  10. Measure of volume of distribution adjusted for bioavailability (Vd/F) of tolododekin alfa

    Characterize pharmacokinetic (PK) parameter Vd/F after IT administration of tolododekin alfa

    Time frame: 6 months

  11. Measure of terminal half-life (t1/2) of tolododekin alfa

    Characterize pharmacokinetic (PK) parameter t1/2 after IT administration of tolododekin alfa

    Time frame: 6 months

  12. Incidence of treatment-emergent anti-drug antibodies (ADA) of tolododekin alfa

    Quantification of ADAs after IT administration of tolododekin alfa

    Time frame: 6 months

07

Study locations

10 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 20 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 18, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2028
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07027514
Lead sponsor
Ankyra Therapeutics, Inc
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Oct 22, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Ankyra Therapeutics
Contact
LANTERN@ankyratx.com
7817185121

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolododekin alfa

Start the discussion